Blueshift Asset Management’s Heron Therapeutics HRTX Stock Holding History

Blueshift Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,847	Closed	-$58K	–	471
2022 Q3	$58K	Buy	+13,847	New	+$54.2K	0.01%	568
2022 Q1	–	Sell	-27,493	Closed	-$251K	–	970
2021 Q4	$251K	Buy	+27,493	New	+$281K	0.02%	693
2021 Q2	–	Sell	-28,221	Closed	-$457K	–	1024
2021 Q1	$457K	Buy	+28,221	New	+$503K	0.05%	492
2019 Q2	–	Sell	-8,851	Closed	-$216K	–	813
2019 Q1	$216K	Buy	+8,851	New	+$232K	0.03%	608

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Blueshift Asset Management's HRTX Position: Q4 2022 in Review

Blueshift Asset Management sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 13,847 shares — an estimated $58K sold.

Blueshift Asset Management first reported a position in HRTX in Q1 2019 and held it in 4 quarters. The position peaked at $457K in Q1 2021. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

Blueshift Asset Management reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
Blueshift Asset Management sold 13,847 Heron Therapeutics shares in Q4 2022, an estimated $58K.
Blueshift Asset Management first reported a position in Heron Therapeutics in Q1 2019 and held it in 4 quarters.
Blueshift Asset Management's Heron Therapeutics position peaked at $457K in Q1 2021.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Blueshift Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.